SCNI Scinai Immunotherapeutics Ltd.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1611747 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY99.2%
TTM net income YoY-273.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-202.3%
Operating margin-575.3%
Net margin-633.6%
FCF margin-461.9%
EBITDA margin-466.9%
Returns
ROE-91.9%
ROA-66.3%
ROIC (approx.)-82.4%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets30.3%
Debt / equity0.00x
Current ratio1.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · USD | FY20222022-12-31 · USD | FY20212021-12-31 · USD |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.31M | $658,000 | — | — | 5,000EUR |
| Cost of revenue | $3.96M | $1.24M | — | — | — |
| Gross profit | -$2.65M | -$580,000 | — | — | — |
| R&D expense | $2.37M | $5.53M | $5.21M | $5.76M | $3.25M |
| SG&A expense | $2.52M | $2.53M | $4.50M | $5.30M | $7.62M |
| Operating income | -$7.54M | -$8.64M | -$9.71M | -$11.06M | -$10.86M |
| Interest expense | — | — | $343,000 | $351,000 | $336,000 |
| Net income | -$8.31M | $4.80M | -$6.50M | -$5.80M | -$8.21M |
| EBITDA | -$6.12M | -$6.99M | -$9.19M | -$10.50M | -$10.39M |
| EPS (basic) | — | — | 0.00 | 0.01 | -0.02 |
| EPS (diluted) | — | — | 0.00 | 0.01 | -0.02 |
| Weighted avg. shares (diluted) | 9.34B | 3.23B | 1.56B | 754.08M | 564.58M |
| Balance sheet | |||||
| Cash & equivalents | $1.66M | $1.96M | $4.87M | $14.21M | $17.52M |
| Receivables | $73,000 | $83,000 | — | — | $325,000 |
| Current assets | $2.05M | $2.39M | $5.45M | $14.37M | $17.84M |
| PP&E, net | $7.79M | $9.19M | $10.82M | $11.24M | $12.39M |
| Total assets | $11.63M | $13.45M | $17.47M | $27.07M | $32.04M |
| Current liabilities | $1.58M | $1.81M | $1.78M | $2.34M | $2.44M |
| Short-term debt | — | — | — | $382,000 | $375,000 |
| Total liabilities | $3.52M | $3.47M | $22.04M | $28.83M | $31.05M |
| Shareholders' equity | $8.10M | $9.98M | -$4.57M | -$1.76M | $982,000 |
| Shares outstanding | 13.87B | 3.41B | 1.86B | 989.29M | 739.05M |
| Cash flow statement | |||||
| Operating cash flow | -$6.03M | -$6.33M | -$9.38M | -$7.26M | -$7.43M |
| Capital expenditure | $24,000 | $12,000 | $637,000 | $836,000 | $139,000 |
| Free cash flow | -$6.05M | -$6.35M | -$10.02M | -$8.10M | -$7.57M |
| Investing cash flow | -$24,000 | -$12,000 | -$637,000 | -$836,000 | -$139,000 |
| Financing cash flow | $5.77M | $3.44M | $1.09M | $6.78M | $21.43M |
| Depreciation & amortization | $1.42M | $1.65M | $514,000 | $562,000 | $471,000 |
| Stock-based compensation | $303,000 | $682,000 | $1.14M | $1.60M | $2.76M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.